High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

MLA

Alemany, Andrea, et al. “High-Titre Methylene Blue-Treated Convalescent Plasma as an Early Treatment for Outpatients with COVID-19: A Randomised, Placebo-Controlled Trial.” The Lancet Respiratory Medicine, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1016/S2213-2600(21)00545-2.

APA

Alemany, A., Millat-Martinez, P., Corbacho-Monné, M., Malchair, P., Ouchi, D., Ruiz-Comellas, A., Ramírez-Morros, A., Rodríguez Codina, J., Amado Simon, R., Videla, S., Costes, G., Capdevila-Jáuregui, M., Torrano-Soler, P., San José, A., Bonet Papell, G., Puig, J., Otero, A., Ruibal Suarez, J. C., Zarauza Pellejero, A., … Grau, E. (2024). High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. The Lancet Respiratory Medicine, Preprints. https://doi.org/10.1016/S2213-2600(21)00545-2

Chicago

Alemany, Andrea, Pere Millat-Martinez, Marc Corbacho-Monné, Pierre Malchair, Dan Ouchi, Anna Ruiz-Comellas, Anna Ramírez-Morros, et al. 2024. “High-Titre Methylene Blue-Treated Convalescent Plasma as an Early Treatment for Outpatients with COVID-19: A Randomised, Placebo-Controlled Trial.” The Lancet Respiratory Medicine, no. Preprints (January). doi:10.1016/S2213-2600(21)00545-2.